Dermatology is one of the most natural fits for UK telehealth — patients can capture images, describe symptoms, and engage with treatment plans without travelling to a clinic. The category is high-volume, evidence-supported, and operationally established. The challenge is staying within the boundaries: some conditions need physical examination, some treatments need specialist-level prescribing, and the regulatory line on advertising prescription medicines is the same here as everywhere else in UK telehealth. This piece is the launch brief for founders entering the category.
Why dermatology suits remote care — and where it does not
Dermatology telehealth in the UK has scaled significantly since 2020. The case for remote care is straightforward: patients can take photographs, describe symptom patterns, and follow treatment plans over months. Conditions like acne, eczema, rosacea, fungal infections, and routine dermatitis are well-suited to image-based assessment supplemented by structured questionnaires.
The boundaries are also clear. Suspected skin cancer or other conditions requiring physical examination should be referred for in-person assessment — image-only diagnosis is not appropriate for lesions requiring biopsy or dermoscopic evaluation. A responsible dermatology telehealth service triages confidently within its scope and refers out clearly when it should.
Clinical scope — what telehealth can responsibly treat
The conditions that fit a UK dermatology telehealth service well: mild-to-moderate acne, eczema and atopic dermatitis, rosacea, seborrheic dermatitis, mild psoriasis, fungal skin infections (with appropriate confirmation), and routine skin care for sensitive or aging skin. These conditions respond to evidence-based treatments that can be prescribed and titrated remotely with structured follow-up.
Conditions that should be referred or require careful triage: suspected skin cancer of any kind, severe acne requiring isotretinoin, severe psoriasis needing systemic immunosuppression, undiagnosed lesions, and any condition where the patient's photographs do not give the clinician confidence in the diagnosis. The clinical pathway should make these triage decisions explicit.
The image-based consultation and photographic standards
Image quality matters in dermatology telehealth — more than in most other telehealth categories. Patient guidance on photograph capture should cover lighting (natural light preferred), distance (close-up plus wider context), focus (clear and stable), and multiple angles where relevant. Patient pathways that accept any uploaded image without quality guidance produce clinical decisions on poor evidence.
Storage, retention, and security of dermatological images is governed by UK GDPR as special-category data. The DPIA should explicitly cover image processing, retention periods, who can access the images, and what happens to them at end of treatment or end of relationship with the patient. Image data security is not just IT hygiene — it is regulatory posture.
Isotretinoin and the categories that need extra care
Isotretinoin prescribing for acne in the UK requires specialist-level care and Pregnancy Prevention Programme adherence under MHRA guidance. The MHRA strengthened safeguards around isotretinoin in 2023 following safety reviews — including mental health monitoring requirements, two-prescriber sign-off for under-18s, and tightened Pregnancy Prevention Programme requirements for patients of childbearing potential.
Telehealth services prescribing isotretinoin must align with this guidance fully: appropriate specialist involvement, structured mental health monitoring, full Pregnancy Prevention Programme adherence, and the supporting clinical-governance framework. Other categories that need extra care: topical corticosteroid use in skin of colour and on facial skin, treatments in pregnancy, paediatric prescribing, and severe presentations.
Patient pathway — diagnosis, prescribing, repeat supply
Standard dermatology telehealth pathways: initial consultation with photographs and structured history, clinical assessment by a qualified prescriber, treatment plan and prescribing decision, follow-up at four to eight weeks for tolerability and early efficacy signal, and ongoing review at three-to-six-month intervals for continuation, switching, or stopping.
Two pathway choices matter most. The first is whether the clinical assessment is documented in detail (differential diagnosis, decision rationale, treatment rationale) or kept superficial. The second is whether photographs and structured re-assessment are part of the review cycle or only triggered by patient complaint. Detailed pathways stand up at inspection; superficial pathways do not.
Regulatory posture and advertising constraints
Dermatology telehealth sits under the standard UK telehealth regulators — GPhC for the dispensing pharmacy, MHRA for medicines, CQC for the clinical service in England, ICO for data including images, ASA for advertising. The category-specific watch point is advertising prescription medicines and making efficacy claims for prescription products in public marketing.
Prescription-only medicines including topical and oral acne treatments cannot be advertised to the public under the Human Medicines Regulations 2012. ASA and MHRA have engaged with skincare and dermatology brands across 2024-2026 over comparative efficacy claims, branded medicine names in marketing, and testimonial-driven advertising. Marketing the clinical service is legitimate; marketing the prescription medicine is not. The distinction is foundational.
How PExpo supports dermatology brand launches
PExpo's brand model includes the clinical workflow with image-handling capability under UK GDPR, a UK prescriber network including dermatology-experienced clinicians, GPhC-compliant dispensing across the topical and oral dermatology range, and the integrations a patient pathway needs — payments, identity, support tooling, and pharmacovigilance capture.
For founders launching a UK dermatology brand in 2026, the build-vs-partner decision on the clinical and dispensing layers is foundational. Building from scratch typically takes 12-18 months including dermatology-specific clinical governance development. Partnering through PExpo's white-label model brings that to 8-12 weeks because the clinical workflow, prescriber network, dispensing, and image-handling infrastructure are pre-integrated. See our brand model page for the full operational scope and our clinic model page if you are a clinic adding dermatology services.
Suspected skin cancer and conditions requiring physical examination should be referred for in-person assessment — image-only diagnosis is not appropriate for lesions requiring biopsy or dermoscopic evaluation. Build clear triage rules into the pathway.
A responsible dermatology telehealth service triages confidently within its scope and refers out clearly when it should.
Launching a UK dermatology telehealth service in 2026 is a defensible build in a category with strong evidence base and broad patient demand. The operators who set clear clinical scope, build proper triage out for conditions needing in-person care, follow MHRA guidance on isotretinoin, and respect POM advertising rules build sustainably. See our brand model page for the white-label launch route, our clinic model page for dermatology inside an existing clinic, and our pricing page for the commercial structure.
Frequently asked questions
What do I need to launch a UK dermatology telehealth service?
A clinical workflow that supports image-based consultations under UK GDPR, a UK prescriber network including dermatology-experienced clinicians, GPhC-registered dispensing across topical and oral dermatology preparations, a triage framework for conditions that need in-person care, and CQC registration in England. PExpo's brand model includes the clinical workflow and dispensing as a managed stack.
Can I prescribe isotretinoin via telehealth in the UK?
Isotretinoin requires specialist-level care and Pregnancy Prevention Programme adherence under MHRA guidance, including post-2023 strengthened safeguards (mental health monitoring, two-prescriber sign-off for under-18s, full PPP adherence). Telehealth services prescribing isotretinoin must implement the full framework — not a subset of it.
How do I handle suspected skin cancer or conditions needing physical examination?
Refer for in-person assessment. Image-only diagnosis is not appropriate for lesions requiring biopsy or dermoscopic evaluation. Build explicit triage rules into the patient pathway and document the referral. The reputational and regulatory cost of getting this wrong is significantly higher than the conversion cost of referring out.
Does PExpo handle dermatology image data securely?
Yes — PExpo's clinical workflow handles dermatological images under UK GDPR special-category data rules with documented retention periods, access controls, and DPIA coverage. See our brand model page for the full data-handling scope.
